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Next-generation sequencing technology makes directly testing rare variants possible. However, existing statistical
methods to detect common variants may not be optimal for testing rare variants because of allelic heterogeneity
as well as the extreme rarity of individual variants. Recently, several statistical methods to detect associations of rare
variants were developed, including population-based and family-based methods. Compared with population-based
methods, family-based methods have more power and can prevent bias induced by population substructure. Both
population-based and family-based methods for rare variant association studies are essentially testing the effect of a
weighted combination of variants or its function. How to model the weights is critical for the testing power
because the number of observations for any given rare variant is small and the multiple-test correction is more
stringent for rare variants. We propose 4 weighting schemes for the family-based rare variants test (FBAT-v) to test
for the effects of both rare and common variants across the genome. Applying FBAT-v with the proposed
weighting schemes on the Genetic Analysis Workshop 19 family data indicates that the power of FBAT-v can be
comparatively enhanced in most circumstances.Background
Hypertension or high blood pressure is a chronic med-
ical condition with unknown complex etiology [1]. Blood
pressure is summarized by 2 measurements: systolic and
diastolic. High blood pressure is said to be present if
blood pressure (BP) is 140 mm Hg systolic or higher
(SBP) or 90 mm Hg diastolic or higher (DBP). More
than 1 billion people worldwide have hypertension [2],
which is a major risk factor for stroke, myocardial infarc-
tion, heart failure, and is a cause of chronic kidney disease
[3–5]. Both genetic and environmental factors are likely to
contribute to this disease. Ehret et al. conducted a large-
scale genome-wide association study of hypertension in
2011 and identified 10 novel loci related to BP physiology
[6]. Although numerous common genetic variants with* Correspondence: jzhou@email.arizona.edu
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(http://creativecommons.org/publicdomain/zesmall effects on BP have been identified [6–8], the identi-
fied variants account for only a small fraction of disease
heritability [9]. One potential source of missing heritability
is the contribution of rare variants. Next-generation se-
quencing technology allows sequencing the whole genome
of large groups of individuals, thus making direct testing
of rare variants feasible.
However, existing statistical methods to detect common
variants may not be optimal for detecting rare variants be-
cause of allelic heterogeneity and the extreme rarity of in-
dividual variants [10]. Recently, several statistical methods
to detect associations of rare variants were developed, in-
cluding both population-based and family-based methods.
Compared with population-based methods, family-based
methods have more power and can prevent bias induced
by population substructure [11]. However, family-based
methods to detect rare variants are not well established,
which may be the result of the difficulties and complex-
ities in testing rare variants in pedigree data. Let ximle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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individual at the mth variant. Both population-based and
family-based methods for rare variant association studies
are essentially testing the effect of a weighted combination
of variants, ∑mwmxim, or its function. How to model the
weights wm is critical for the testing power because the
number of observations for any given rare variant is small
and the multiple-test correction is more stringent for rare
variants [12]. Family-based association tests for rare vari-
ants (FBAT-v) is a recently developed family-based
method. In their paper on FBAT-v, De et al. used a weight-
ing scheme based on allele frequency and noted that the
optimal weighting scheme is unknown and dependent on
the underlying disease model [11]. To powerfully test rare
variants using family-based tests for hypertension based
on the Genetic Analysis Workshop 19 (GAW19) data and
to provide a powerful means to test the rare variants that
play an important role in a disease etiology, we propose
and evaluate 4 weighting schemes for the FBAT-v.
The GAW19 data consists of a whole genome sequen-
cing data set for a large-scale pedigree-based sample that
includes 959 individuals. Among the 959 individuals,
849 have simulated phenotypes in all 200 replicates. Our
analysis focuses on the family data of the 849 individ-
uals. We applied FBAT-v with the proposed weighting
schemes to the GAW19 family data. Our results indicate
that the type I error rates for all the methods compared
are under control and the power of the FBAT-v with an
optimal weight outperforms the methods compared in
most circumstances.
Methods
Consider a sample of n trios. Each individual in the sam-
ple has been genotyped at M variants in a genomic region.
Denote yi as the quantitative trait for the i
th offspring.
Denote Xi = (xi1,…, xiM)
T as the genotypic score of the ith
individual, where xim ∈ {0, 1, 2} is the number of minor
alleles that the ith individual has at the mth variant.
Suppose that we have p covariates. Let (zi1,…, zip)
T de-
note covariates of the ith individual. We adjust both trait
value yi and genotypic score xim for the covariates by
applying linear regressions. That is,
yi ¼ α0 þ α1zi1 þ…þ αpzip þ εi and xim
¼ α0m þ α1mzi1 þ…þ αpmzip þ τim
Let ỹi and ~xim denote the residuals of yi and xim, re-
spectively. Denote ~Xi ¼ ~xi1;…; ; ~xiMð Þ as the residuals of
the genotypic score of the ith individual.
To test the null hypothesis of no association, the
weighted family-based association test (FBAT) statistic
for rare variants (FBAT-v) [11] can be defined as
Z ¼ W wð Þ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var W wð Þ






~yi−μð Þ ~xim−Eð~ximjPimð Þ;
μ is the mean of the trait and Pim is the parental genotypes
for the ith family of the mth variant:
Z approximately follows N(0,1) in large samples under
the null hypothesis of no association. For large pedi-
grees, pedigrees are decomposed into nuclear families
which are treated as independent unless a trait locus is
known to be linked to the markers under test. The pedi-
gree’s contribution to the tests statistic is obtained by
summing over all nuclear families within the pedigree.
However, in the case where linkage is present and the
null hypothesis states “no association but linkage pre-
sents,” the genotypes of the different nuclear families
derived from 1 pedigree are correlated. In this case, the
variance of W(w) should be computed empirically in
order to keep the type I error rates under control.
To increase the power of FBAT-v, we propose the fol-
lowing 3 weighting schemes that use only founders’ in-
formation. In the family data, founders are individuals
who have no parents specified (assuming l founders in
total): genotype risk value (grv); log odds ratio (lor); and
optimal weight (ow).
Genotype risk value
The genotype risk value (grv) weighting scheme is based
on genotype frequencies and effect sizes for each single-
nucleotide polymorphism (SNP) from the single-variant
study. Comparing the continuous trait with a prespeci-
fied threshold, we can classify subjects into 2 categories:
cases and controls. Assume that AA, AB, and BB (A,
low-risk allele; B, high-risk allele) are genotypes for a
SNP. Based on the log-additive model, the 3 genotypes
have a relative risk of 1, odds ratio (OR), OR2, respect-
ively. If the B allele has frequency p, then the average
relative risk (ARR) in the population can be calculated
as: ARR = (1 − p)2 + 2p(1 − p)OR + p2OR2. 1/ARR, OR/
ARR, and OR2/ARR are assigned as weights for genotype
AA, AB, and BB, respectively. This weighting scheme
puts big weights on variants with more copies of the risk
alleles.
Log odds ratio
The log odds ratio (lor) weighting scheme is based on ef-
fect size for each SNP from the single-variant study.
Similarly, comparing the continuous trait with a prespe-
cified threshold (eg, SBP = 140 mm Hg), we can classify
subjects into 2 categories: cases and controls. We can
then build a logistic regression model by adjusting for
covariates such as age, gender, and smoking status. The
weight for each individual SNP is determined by the lor
of its association with disease. This weighting scheme
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ciated with disease.Optimal weight
The optimal weight (ow) ws
o was first proposed by Sha
et al. [13] in a population-based test TOW (test for test-
ing the effect of an optimally weighted combination of
variants) by assuming the independence among rare
variants:






vuut ; where ρ is the correl-
ation coefficient between trait value residuals ỹ of unre-
lated individuals and genotypic score residuals. This
weighting scheme gives large weights to rare variants
that have small allele frequencies and strong associations
with the trait of interest.
All the aforementioned weighting schemes—grv, lor,
and ow—can adjust the direction of the association,
which potentially can boost power of FBAT-v as FBAT-v
only focuses on all the variants having effects in the
same directions and can lead to lower power when there
are variants with effects in the opposite directions. In
addition to the aforementioned weighting schemes, we
also propose to use functional prediction scores as
weights in FBAT-v. By incorporating computational
predictions of the functional effects of nonsynon-
ymous variants into FBAT-v, it can avoid the loss of
power that results from combining both functional
and nonfunctional variants [12].Functional prediction
Price et al. [12] first incorporated computational predic-
tions of the functional effects of missense variants in
their statistical test and reported that incorporating
computational predictions of functional importance fur-
ther boosted power. In this study, we investigate whether
incorporation of PolyPhen-2 scores as weights improves
the FBAT-v test. We use SnpEff (http://snpEff.sourcefor-
ge.net) [14] to predict nonsynonymous, splice, and stop
variants, and to obtain the predicted functional scores of
all nonsynonymous SNPs with PolyPhen-2 algorithm
(http://genetics.bwh.harvard.edu/pph2) [15]. We assignTable 1 Type I error of FBAT-v with different weighting schemes an
Significance level
(95 % CI) FBAT-v-e FBAT-v-e-grv
0.01 (−0.004, 0.024) 0.005 0.01
0.05 (0.02, 0.08) 0.065 0.060
0.1 (0.058, 0.142) 0.11 0.1
CI confidence interval, FBAT-v-e FBAT-v with weighted sum weights as in De et al. [1
weights using empirical variance, FBAT-v-e-grv FBAT-v with genotype risk value (grv
weights using empirical variance, FBAT-v-e-ow FBAT-v with optimal weight (ow) weiweights equal to the PolyPhen-2 score for nonsynon-
ymous SNPs and 0 otherwise. For those nonsynonymous
SNPs without a prediction score, we impute them with
the corresponding median prediction score of a gene.
Results
We apply the FBAT-v method incorporating the pro-
posed weighting schemes—grv, lor, ow, and functional
prediction (fp)—to the GAW19 family data, which con-
sists of a whole genome sequencing data set for a large-
scale pedigree-based sample of 959 individuals. Among
the 959 individuals, 849 have simulated phenotypes in
all 200 replicates. Our analysis focuses on the family data
of the 849 individuals. The genotype, phenotype, and
other information of 108 founders (unrelated individ-
uals) out of the 849 individuals are used to calculate the
grv, lor, and ow weights.
To evaluate type I error rates and the power of FBAT-v
incorporating the 4 different weighting schemes, we em-
ploy the complete set of 200 replicates in the GAW19
family data. Significance is assessed in significance levels
of 0.1, 0.05, and 0.01. For power comparisons, FBAT-v
with the 4 weighting schemes is compared with FBAT-v
with the weighting scheme based on allele frequencies as
in De et al. [11]. In our analyses, we focus on 2 continuous
phenotypes: SBP and DBP. The estimated heritability for
SBP and DBP is in the range of 20–30 % [16]. We apply
linear regression for each exam by adjusting for age, sex,
and BP meds (ie, current use of antihypertensive medica-
tions) to generate standardized residuals for traits and
genotypic scores. Our final analysis is based on the aver-
age residuals over 3 examinations.
Type I error
To estimate the type I error rates, using our proposed
approaches, we test association between the simulated
trait Q1 and a region including 28 SNPs selected from
gene MAP4 of chromosome 3. Q1 in the family data set
is simulated as a normally distributed quantitative trait
that is correlated among family members (additive gen-
etic heritability = 0.68), but not influenced by any of the
genotyped SNPs. Therefore, any observed associations
are false positives. Table 1 shows the type I error rate of






1] using empirical variance, FBAT-v-e-fp FBAT-v with functional prediction (fp)
) weights using empirical variance, FBAT-v-e-lor FBAT-v with log odds ratio (lor)
ghts using empirical variance
Table 2 Summary statistics of the top 5 genes
Gene CHR Position No. of SNPs No. of FV MAF <1 % MAF <5 % TVE (%)
MAP4 3 (47892180, 48130769) 894 15 621(69.46 %) 740(82.71 %) 6.48
TNN 1 (175036994, 175117202) 533 18 224(42.03 %) 274(51.41 %) 4.08
NRF1 7 (129251555, 129396922) 740 14 385(51.33) 489(66.08 %) 2.65
LEPR 1 (65886335, 66103176) 980 8 380(38.78 %) 516(52.65 %) 2.5
FLT3 13 (28577411, 28682904) 849 10 340(40.04 %) 488(57.48 %) 1.22
CHR chromosome, FV functional variants, MAF minor allele frequency, TVE total variance explained
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empirical variance (FBAT-v-e); FBAT-v with grv weights
using empirical variance (FBAT-v-e-grv); FBAT-v with
lor weights using empirical variance (FBAT-v-e-lor);
FBAT-v with ow weights using empirical variance
(FBAT-v-e-ow); and FBAT-v with fp weights using em-
pirical variance (FBAT-v-e-fp). The type I error rates of
FBAT-v with all the 5 weighting schemes are under
control.Power comparison
To evaluate the performance of our approaches, we
compare the power of FBAT-v-e, FBAT-v-e-grv, FBAT-v-
e-lor, FBAT-v-e-ow, and FBAT-v-e-fp in detecting asso-
ciation between SBP or DBP and the top 5 genesTable 3 Power comparisons of FBAT-v with different weighting sch
Gene Power of Tests
FBAT-v-e FBAT-v-e-grv


















FBAT-v-e FBAT-v with weighted sum weights as in De et al. [11] using empirical vari
variance, FBAT-v-e-grv FBAT-v with genotype risk value (grv) weights using empirica
variance, FBAT-v-e-ow FBAT-v with optimal weight (ow) weights using empirical vari(MAP4, TNN, NRF1, LEPR, and FLT3) influencing simu-
lated SBP or DBP.
Genes were defined by transcription start and end po-
sitions obtained from the University of California Santa
Cruz (UCSC) Genome Browser hg19 build (http://
genome.ucsc.edu/). Table 2 shows the summary statis-
tics of the top 5 genes that influence simulated SBP
and DBP. The total variance explained by each of the
5 genes is greater than 1 %. The percentage of rare
variants in each gene is more than 50 % with a minor
allele frequency (MAF) of less than 5 %, and greater
than 38 % with a MAF of less than 1 %.
Table 3 indicates power of the compared methods for
association study in each gene. Because MAP4 can ex-
plain 6.48 % of the disease heritability and it has 69.46 %

















ance, FBAT-v-e-fp FBAT-v with functional prediction (fp) weights using empirical
l variance, FBAT-v-e-lor FBAT-v with log odds ratio (lor) weights using empirical
ance
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MAP4. In general, compared with FBAT-v-e by only
considering allele information, FBAT-v-e-ow performs
better with additional genetic effect information ob-
tained from the unrelated individuals. The power of all
the methods is pretty small for all other 4 genes. Two of
the possible reasons are the ability to explain the lower
percentage of rare variants (<51 %) and the lower herit-
ability (<5 %). We did notice that FBAT-v-e-fp performs
better in gene TNN than other methods. One possible
reason is that there are more functional variants residing
on this gene.
Discussion and conclusions
In this article, we propose 4 weighting schemes for the
FBAT-v. Simulation studies indicate that both the grv
and ow weighting schemes can boost FBAT-v’s power
when the proportion of rare variants is large (eg, 69 %
with a MAF of <1 %) and total variance being explained
is relatively big (eg, 6.48 %). However, when the total
variance being explained is less than 5 %, all of the
methods have almost no power to detect rare variants.
One possible reason is that the FBAT is essentially a
burden-type test. Although the proposed weighting
schemes of grv, lor, and ow can adjust the direction of
the association, it still can lose power when rare variants
in a gene act in different directions on phenotypes. A
variance-component based FBAT [17] could be much
more powerful in such instances. Further study of what
causes the power loss when detecting association on the
other 4 genes with the FBAT-v–based methods is
needed.
The proposed weights grv and lor are based on the
effect size estimates from the marginal association. How-
ever, estimates are not stable when the variants are rare.
This can be reflected from the unstable power of FBAT-
v-e-grv and FBAT-v-e-lor when detecting gene NRF1 in
Table 3.
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